Levetiracetam

證據等級: L5

預測適應症: 10 個

Levetiracetam: From Epilepsy to Visual Epilepsy

One-Sentence Summary

Levetiracetam is a second-generation antiseizure medication, historically established for epilepsy and seizure disorders (marketed internationally as Keppra®). The TxGNN model predicts it may also be effective for Visual Epilepsy, a photosensitive reflex-epilepsy subtype, with 9 clinical trials and 20 publications currently associated with this candidate — though most of this evidence addresses levetiracetam in epilepsy/seizures broadly rather than visual epilepsy specifically.

Quick Overview

Item	Content
Original Indication	Epilepsy / seizure disorders (general knowledge — not present as a structured field in the evidence pack; see note below)
Predicted New Indication	Visual Epilepsy
TxGNN Prediction Score	99.98%
Evidence Level	L2
Denmark Market Status	Not Marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed structured mechanism-of-action data is not available in DrugBank for this candidate (flagged as a data gap, DG002). However, the collected literature itself describes the mechanism: levetiracetam is a “new generation antiseizure medication which binds to synaptic vesicle protein SV2A and inhibits the release of neurotransmitters” (PMID 35848684), and earlier work similarly describes it as binding synaptic vesicle protein 2A (SV2A) to modulate neurotransmitter release (PMID 34903423). This SV2A-binding mechanism underlies its broad anticonvulsant activity across seizure types.

Visual epilepsy (photosensitive/reflex epilepsy triggered by visual stimuli) is mechanistically a subtype of the broader epilepsy spectrum that levetiracetam already treats. The evidence pack for this candidate is dominated by trials and publications on levetiracetam across other seizure contexts — traumatic brain injury, intracerebral haemorrhage, neonatal seizures, status epilepticus, and idiopathic generalized epilepsy — rather than visual/photosensitive epilepsy specifically. This supports a plausible mechanistic rationale (an established anticonvulsant extending to a related seizure phenotype) but direct evidence for visual epilepsy itself is currently limited; it is not yet backed by trials or publications diagnosing or targeting this specific reflex-epilepsy subtype.

Because the original indication is not populated as a structured field in this evidence pack, the “original indication” above is stated from general drug knowledge (consistent with how mechanism-of-action gaps are handled) rather than sourced data — this should be confirmed against the formal record before use.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04573803	Phase 3	Not yet recruiting	1649	MAST trial — optimal duration/choice (phenytoin vs levetiracetam) of anti-epileptic drugs after traumatic brain injury
NCT00855738	Phase 4	Completed	111	Liceo study — observational assessment of newer AEDs (incl. levetiracetam) as first bitherapy in focal epilepsy
NCT07336992	Phase 3	Not yet recruiting	580	Prophylactic levetiracetam for functional outcome in acute intracerebral haemorrhage (RCT, placebo-controlled)
NCT03107507	Phase 4	Unknown	40	Efficacy of levetiracetam in control of neonatal seizures
NCT04833907	Phase 1/2	Enrolling by invitation	24	AVASPA gene therapy trial in Canavan disease (levetiracetam relevance unclear from summary)
NCT00105040	Phase 2	Completed	87	Randomized, double-blind, placebo-controlled safety study of cognitive/neuropsychological effects of adjunctive levetiracetam in children with refractory partial seizures
NCT04559529	Phase 2	Completed	62	Levetiracetam’s effect on hippocampal hyperactivity in psychosis (fMRI study)
NCT04277936	Phase 2	Terminated	1	Levetiracetam’s effect on hippocampal hyperactivity in psychosis (terminated early)
NCT00203216	N/A	Completed	31	Open-label trial of levetiracetam (Keppra®) for prophylactic treatment of migraine, with/without visual aura

No trial in this set is registered specifically for “visual epilepsy”; relevance grading for all listed trials is still marked “pending” in the source data.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35963261	2022	RCT (Phase 3)	The Lancet Neurology	PEACH trial — prophylactic levetiracetam did not show clear benefit preventing acute seizures after intracerebral haemorrhage
32385134	2020	RCT	Pediatrics	Levetiracetam vs phenobarbital for neonatal seizures
38678766	2024	RCT	Seizure	Open-label RCT of phenytoin vs levetiracetam for acute symptomatic seizures in children with acute encephalitis syndrome
30487494	2018	RCT	Mymensingh Medical Journal	RCT of phenobarbital vs levetiracetam in childhood epilepsy
34286461	2022	Systematic Review/Meta-analysis	Neurocritical Care	Levetiracetam for seizure prophylaxis in neurocritical care (ICH, TBI, SAH, post-neurosurgery)
38316735	2024	Clinical Practice Guideline	Neurocritical Care	Guideline on seizure prophylaxis in adults hospitalized with moderate-severe TBI
36209676	2022	Systematic Review/Network Meta-analysis	Seizure	Comparative effectiveness of treatments for benzodiazepine-resistant status epilepticus
37378757	2023	Systematic Review/Network Meta-analysis	Journal of Neurology	Efficacy/safety of antiseizure medications for idiopathic generalized epilepsies
40450767	2025	Systematic Review/Meta-analysis	Epilepsy & Behavior	Levetiracetam for myoclonic seizures in idiopathic generalized epilepsy (incl. JME)
21936590	2011	Review	CNS Drugs	“Spotlight on levetiracetam in epilepsy” — overview of approved indications and pharmacology

None of the top publications are specific to “visual epilepsy”; the closest directly relevant evidence for reflex/photosensitive epilepsy subtypes appears under other TxGNN-predicted candidates in this same pack (e.g., startle epilepsy, audiogenic seizures), not under this indication’s own evidence set.

Denmark Market Information

Levetiracetam currently has no registered marketing authorisation in this evidence pack (market_status: 未上市 / Not Marketed, total_licenses: 0). This appears inconsistent with levetiracetam’s well-established international marketing status (e.g., as Keppra®), so this record should be verified directly against the Laegemiddelstyrelsen (Danish Medicines Agency) product register before relying on it.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. No structured warnings, contraindications, or drug-interaction data were returned for this candidate (DDI query status: not found), and this data gap is flagged as Blocking for safety pre-assessment (DG001).

Conclusion and Next Steps

Decision: Hold

Rationale: A Blocking data gap exists — no TFDA/SmPC-equivalent warnings or contraindications are available, which prevents any safety pre-assessment (S1). In addition, Denmark shows zero marketing authorisations on file (a status that itself warrants verification), and the evidence collected for “visual epilepsy” specifically is thin — most trials/publications address levetiracetam in epilepsy or seizure contexts broadly, not this reflex-epilepsy subtype.

To proceed, the following is needed:

Danish/EU SmPC or labeling data (warnings, contraindications, DDI) to clear the Blocking data gap (DG001)
Structured DrugBank MOA confirmation (DG002) — current MOA description is derived from literature abstracts, not a structured source
Verification of Denmark market/licensing status against the Laegemiddelstyrelsen registry (data pack shows 0 licenses, which is unexpected for a long-established antiepileptic)
Trial/literature evidence specifically targeting visual epilepsy or photosensitive reflex epilepsy, rather than epilepsy/seizures generally
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.